KOL Insight Archives | Report Store

Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #2

A US key opinion leader (KOL) discusses the approach to treating major depressive disorder as well as the most pressing unmet needs in the market, and provides insights into key late-phase pipeline drugs for major depressive disorder.

October 2, 2018

Find out more

2016 Biomedtracker ASCO Survey

$599.00

Biomedtracker performed a 5-question survey of 39 United States and European (France, Germany, Italy, and United Kingdom) oncologists after the American Society of Clinical Oncology (ASCO) meeting to gauge interest in new data presented on drugs in clinical development.

June 8, 2016

Find out more

Schizophrenia and Bipolar Disorder KOL Interview – Germany

$599.00

This interview with an EU-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

April 28, 2021

Find out more

Datapack – Pharmaprojects Pharma R&D Annual Review 2017

$1,999.00

This datapack presents the supporting data behind the seminal white paper, Pharma R&D Annual Review 2017. The white paper is available for free for Biomedtracker subscribers.

April 18, 2017

Find out more

Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – US, Midwest

$599.00

A US key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.

January 8, 2019

Find out more

2015 Breast Cancer Pulse #3

$599.00

We performed a 5-question survey of 25 oncologists in the US to gauge current prescribing practices for breast cancer treatments.

June 12, 2015

Find out more

HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #1

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HIV PrEP. Drug pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include islatravir and cabotegravir.

August 10, 2021

Find out more

Breast Cancer Pulse Survey

$599.00

Drugs and drug candidates discussed:

palbociclib, neratinib, Herceptin, Perjeta, Kadcyla, Tykerb, Afinitor

April 23, 2014

Find out more

Prostate Cancer KOL Interview – US

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Diagnostic testing and unmet needs are also discussed. Key pipeline assets highlighted include Keytruda, Tecentriq, ipatasertib, DCVAC/PCa, capivasertib, Lutetium 177Lu-PSMA-617, and Cabometyx.

November 10, 2020

Find out more

Anemia in Chronic Kidney Disease KOL Interview – US, East Coast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for anemia in chronic kidney disease (CKD). Key topics discussed include current treatments for anemia in CKD, with a focus on ESAs and IV iron, and the future of HIF stabilizers as a potential treatment for the disease.

June 30, 2020

Find out more

Datamonitor Healthcare HIV KOL Interview – UK

$599.00

A UK key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

January 25, 2019

Find out more

Type 1 Diabetes KOL Interview – UK

$599.00

This interview with a UK Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes.

January 8, 2020

Find out more

ECLIPSE Psoriasis Pulse Survey

$599.00

This 11-question pulse survey of 74 dermatologists practicing throughout the US and Europe asks respondents their thoughts on results from the ECLIPSE study

January 31, 2019

Find out more

Datamonitor Healthcare Type 2 Diabetes KOL Interview – US

$599.00

In this discussion with a US KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.

October 12, 2018

Find out more

Anemia in Chronic Kidney Disease KOL Interview – US, West Coast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for anemia in chronic kidney disease (CKD). Key topics discussed include current treatments for anemia in CKD, with a focus on ESAs and IV iron, and the future of HIF stabilizers as a potential treatment for the disease.

June 30, 2020

Find out more

2018 ASH Pulse Survey

$599.00

This 9-question pulse survey of 102 hematologic oncologists practicing throughout the United States and Europe.

January 2, 2019

Find out more

Non-Small Cell Lung Cancer KOL Interview

$599.00

Biomedtracker interviewed a lung cancer specialist based in the US to determine his views on the non-small cell lung cancer treatment landscape, with a focus on PD-1 immunotherapies.

December 16, 2016

Find out more

Follicular Lymphoma KOL Interview – US

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for follicular lymphoma. Disease stratification by staging and expression, as well as unmet needs, are also discussed. Key assets highlighted include Rituxan, Revlimid, Gazyva, Yescarta, Imbruvica, Kymriah, and mosunetuzumab.

July 16, 2021

Find out more

Datamonitor Healthcare Chronic Heart Failure KOL Interview – US, Southwest

$599.00

A US KOL provides insight into marketed and pipeline therapies for chronic heart failure, as well as key unmet needs in this therapeutic area. Key marketed drugs are highlighted, including Corlanor and Entresto. Significant late-phase pipeline drugs are also covered, with a focus on SGLT-2 inhibitors.

February 4, 2019

Find out more

Biosimilars and Reimbursement KOL Interview

$599.00

Topics: Biosimilars and Reimbursement

Physician Information

Specialty: Specialty Pharmaceuticals

Location: Alexandria, VA

July 31, 2015

Find out more

Treatment of VTE – EU KOL Interview

$599.00

This interview with an EU vascular physician explores the dynamics in the 5 major European markets regarding the introduction of novel/direct oral anticoagulants (NOAC, DOAC) in the treatment of venous thromboembolism (VTE) and prevention of recurrence.

November 4, 2015

Find out more

Datamonitor Schizophrenia KOL Interview

$599.00

On key factors effecting treatment: “First of all tolerability, because if the tolerability is not good then there will be no adherence. The second is efficacy, and the third one maybe is also whether the compound is also available as a depot. I think that is a major advantage if a drug, if an antipsychotic, is indeed available as a depot or as a long-acting injection (LAI).”

February 10, 2016

Find out more

Breast Cancer KOL Insight Interview

$599.00

Physicians are starting to use Perjeta (Roche) as an add-on to Herceptin in the adjuvant setting due to a recent
change in NCCN (National Comprehensive Cancer Network, an alliance of major cancer centers) guidelines.

May 8, 2014

Find out more

2015 PCSK9 Inhibitors Pulse

$599.00

Following the approval of the first PCSK9 Inhibitor, Praluent (SNY, REGN), this 5- question survey of 23 cardiologists evaluated attitudes towards the class, projected usage prior to their CVOTs depending on insurance prior authorization, preference of Praluent vs Repatha (AMGN), and how the oral CETP inhibitors would impact PCSK9 usage under different outcomes study scenarios.

August 19, 2015

Find out more

Post-EASL KOL Interview

$599.00

Highlights KOL believes elsbasvir and grazoprevir data will lead to approval and look similar to available drugs on the market (MRK). Post-liver transplant data for sofosbuvir and simpeprevir was positive (GLD, JNJ). Three DAA combination of -5816,-9857, and sofosbuvir looked good, but most physicians are erring on the side of conservative 12- week treatment regimens […]

May 29, 2015

Find out more

Dermatology KOL Interview

$599.00

BioMedTracker – Dermatology KOL Interview In recent years, patients have become more comfortable with aesthetic dermatology procedures as they have become more widespread.

October 31, 2014

Find out more

Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – UK

$599.00

A UK key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.

January 8, 2019

Find out more

Aromatase Resistance and Palbociclib for Breast Cancer

$89.00

These pathways can be targeted either at the cell surface receptor

level or their downstream signaling cascades. Currently, everolimus in combination with

exemestane represents a new standard of care for patients progressing on non-steroidal AIs.

HDAC inhibitors have also shown promising results For innate resistance, the combination of

fulvestrant and AI in the front line setting represents a new treatment option, particularly for

patients who present with de novo metastatic disease.

April 1, 2014

Find out more

Alzheimer’s Disease KOL Interview – UK

$599.00

This interview with a UK key opinion leader (KOL) provides an overview of cost-effectiveness criteria that may be required to bring Alzheimer’s disease products successfully to the clinic in the UK. We also discuss current and potential treatment options, as well as unmet needs in Alzheimer’s disease.

January 20, 2019

Find out more

Multiple Myeloma KOL Interview – US

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for multiple myeloma. Drug adverse events and critical unmet needs are also discussed. Key therapies highlighted include Darzalex, Venclexta, Xpovio, Ygalo, Blenrep, and BCMA-targeted CAR-T therapies.

May 15, 2020

Find out more

Triple-Negative Breast Cancer KOL Interview – UK

$599.00

A UK-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include balixafortide, Keytruda, sacituzumab govitecan, trastuzumab deruxtecan, and veliparib.

October 31, 2019

Find out more

Non-Small Cell Lung Cancer KOL Interview – NH, US

$1,099.00

Datamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-1/L1 inhibitors to gauge his views

August 30, 2018

Find out more

Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – UK

$599.00

An interview with a UK key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline approaches, and addressing unmet needs.

November 12, 2018

Find out more

MDS/AML KOL Interview

$599.00

Highlights More specific, next-generation FLT3 inhibitors may not have an anti-leukemic benefit over agents with broader TKI activity (such as sorafenib, AMGN), but they may not have as severe myelosuppressive effects. Although the kinase inhibitor rigosertib (ONTX) had poor Phase III results in MDS and AML, the subgroup of patients with primary HMA failure may […]

April 9, 2015

Find out more

Epilepsy KOL Interview – US, West

$599.00

A US key opinion leader (KOL) discusses the epilepsy treatment landscape, including new market entrant Epidiolex, and provides their perspective on late-phase pipeline anti-epileptic drugs such as Fintepla.

February 18, 2019

Find out more

Anemia in Chronic Kidney Disease Pricing & Reimbursement KOL Interview – US, Southwest

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into pricing and reimbursement dynamics and issues concerning anemia in chronic kidney disease, with a focus on the anticipated reimbursement of HIF stabilizers in the US.

June 30, 2020

Find out more

Datamonitor Healthcare Systemic Lupus Erythematosus KOL Interviews

$599.00

Datamonitor Healthcare interviewed two experts on systemic lupus erythematosus (SLE) based in the US to gauge their views on currently available treatment options, pipeline drugs and challenges with clinical trial design in SLE.

August 18, 2017

Find out more

Psychiatry KOL Insight Interview

$599.00

At SfN, they showed some interesting preclinical data on the affect on the 5-HT7 and how it works in some animal models of cognition…especially those injected with PCPA. And you know in depression, they also did what we call the chronic mild stress (CMS)

January 24, 2014

Find out more

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – France

$599.00

This interview with a French key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies and future treatment rates for the different fibrosis stages of NASH.

May 20, 2019

Find out more

2015 Post-AAIC KOL Interview

$599.00

Following the 2015 Alzheimer’s Association International Conference (AAIC), we interviewed an Alzheimer’s Disease expert on his opinion of the data presentations and the future of Alzheimer’s Disease treatment.

August 1, 2015

Find out more

Alzheimer’s Disease KOL Interview – US, Northeast

$599.00

This interview with a US key opinion leader (KOL) provides insight into data from various late-phase Alzheimer’s disease pipeline therapies, as well as a discussion of the design of these trials. Also discussed are treatment trends and current unmet needs.

January 28, 2019

Find out more

HER2+ Breast Cancer KOL Interview – UK

$599.00

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HER2+ breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include Enhertu, tucatinib, margetuximab, and the subcutaneous fixed-dose combination of Herceptin and Perjeta.

March 3, 2020

Find out more

Datamonitor Healthcare Chronic Heart Failure KOL Interview – UK

$599.00

A UK KOL provides insight into marketed and pipeline therapies for chronic heart failure, as well as key unmet needs in this therapeutic area. Key marketed drugs are highlighted, including Corlanor and Entresto. Significant late-phase pipeline drugs are also covered, with a focus on SGLT-2 inhibitors.

February 4, 2019

Find out more

HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #2

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HIV PrEP. Drug pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include islatravir and cabotegravir.

August 10, 2021

Find out more

Non-Small Cell Lung Cancer (NSCLC) KOL Interview – UK

$599.00

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for non-small cell lung cancer (NSCLC). Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include AMG 510, MRTX849, capmatinib, tepotinib, TAK-788, poziotinib, pralsetinib, and selpercatinib.

March 23, 2020

Find out more